Category «PHASE 3»

Devimistat

Devimistat CPI-613 Molecular Weight 388.59 Formula C₂₂H₂₈O₂S₂ CAS No. 95809-78-2 SMILES O=C(O)CCCCC(SCC1=CC=CC=C1)CCSCC2=CC=CC=C2 phase III, hematological cancer 6,8-Bis(benzylsulfanyl)octanoic acid Octanoic acid, 6,8-bis[(phenylMethyl)thio]- Octanoic acid, 6,8-bis((phenylmethyl)thio)- Rafael Pharmaceuticals (formerly Cornerstone Pharmaceuticals), a subsidiary of Rafael Holdings, is developing devimistat, the lead candidate from a program of thioctans and their derivatives that act as pyruvate dehydrogenase and alpha-ketoglutarate …

Esketamine

Esketamine Molecular FormulaC13H16ClNO Average mass237.725 Da (+)-Ketamine (2S)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone (S)-Ketamine 33643-46-8 [RN] 7884 Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2S)- Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (S)- Ketamine CAS Registry Number: 6740-88-1 CAS Name: 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone Molecular Formula: C13H16ClNO Molecular Weight: 237.73 Percent Composition: C 65.68%, H 6.78%, Cl 14.91%, N 5.89%, O 6.73% Literature References: Prepn: C. L. Stevens, BE634208; idem,US3254124 (1963, 1966 both to Parke, Davis). Isoln of optical isomers: T. W. Hudyma et …

BINDARIT

BINDARIT Molecular FormulaC19H20N2O3 Average mass324.374 Da CAS 130641-38-2 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid 2-[(1 -benzyl-1 H-indazol-3-yl)methoxy]-2-methylpropanoic acid 2-[(1-benzyl-1H-indazol-3-yl)methoxy]-2-methylpropanoic acid JQ11LH711M Propanoic acid, 2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]- [ACD/Index Name] биндарит [Russian] [INN] بينداريت [Arabic] [INN] 宾达利 [Chinese] [INN] PHASE 2 Bindarit has been used in trials studying the prevention and treatment of Coronary Restenosis and Diabetic Nephropathy. Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss …

Roluperidone

Molecular FormulaC22H23FN2O2 Average mass366.429 Da Roluperidone CAS 359625-79-9 1937215-88-7 hcl ролуперидон [Russian] [INN] رولوبيريدون [Arabic] [INN] 罗鲁哌酮 [Chinese] [INN] 1H-Isoindol-1-one, 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]methyl]-2,3-dihydro- 2-({1-[2-(4-Fluorophenyl)-2-oxoethyl]-4-piperidinyl}methyl)-1-isoindolinone 2-[[1- [2–fluorophenyl) -2-oxotyl] piperidine –4-yl] methyl] isoindrin-hydrochloride CYR-101 UNII-4P31I0M3BF MIN-101 SYN Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia.[1][2][3][4] One of its metabolites also has some affinity for the H1 receptor.[2] As of May 2018, the drug is in phase III clinical trials.[5] …

REPROXALAP

REPROXALAP レプロキサラップ; ADX-102 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol C12H13ClN2O, 236.7 g/mol CAS 916056-79-6 UNII-F0GIZ22IJH 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol Phase 3 Clinical Aldeyra Therapeutics is developing reproxalap, which binds and traps free aldehydes, formulated using Captisol technology licensed from Ligand Pharmaceuticals as an eye drop formulation, for treating acute noninfectious anterior uveitis, allergic conjunctivitis and dry eye syndrome. PATENT product case, WO2006127945 , EU …

Odevixibat

Odevixibat A-4250, AR-H 064974 CAS 501692-44-0 BUTANOIC ACID, 2-(((2R)-2-((2-((3,3-DIBUTYL-2,3,4,5-TETRAHYDRO-7-(METHYLTHIO)-1,1-DIOXIDO-5-PHENYL-1,2,5-BENZOTHIADIAZEPIN-8-YL)OXY)ACETYL)AMINO)-2-(4-HYDROXYPHENYL)ACETYL)AMINO)-, (2S)- (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1λ6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid Molecular Formula C37H48N4O8S2 Molecular Weight 740.929 AZD8294WHO 10706AR-H064974HY-109120CS-0078340D11716US9694018, 5Originator Albireo AB Developer Albireo AB; Albireo Pharma ClassAcetamides; Butyric acids; Hepatoprotectants; Small molecules; Sulfones; Thiazepines Mechanism of Action Sodium-bile acid cotransporter inhibitors Orphan Drug Status Yes – Primary biliary cirrhosis; Biliary atresia; Intrahepatic cholestasis; Alagille syndrome New Molecular Entity Yes Phase …

CILOFEXOR

CILOFEXOR C28H22Cl3N3O5 , 586.8 g/mol 1418274-28-8 GS-9674, Cilofexor (GS(c)\9674) UNII-YUN2306954 YUN2306954 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid Cilofexor is under investigation in clinical trial NCT02943447 (Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis). Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic …

Remdesivir, レムデシビル , ремдесивир , ريمديسيفير , 瑞德西韦 ,

Remdesivir Formula C27H35N6O8P CAS 1809249-37-3 Mol weight 602.576 レムデシビル UNII:3QKI37EEHE ремдесивир [Russian] [INN] ريمديسيفير [Arabic] [INN] 瑞德西韦 [Chinese] [INN] 2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoate (non-preferred name) L-Alanine, N-((S)-hydroxyphenoxyphosphinyl)-, 2-ethylbutyl ester, 6-ester with 2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-D-altrononitrile 2-Ethylbutyl (2S)-2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 2-Ethylbutyl (2S)-2-[[(S)-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy]phenoxyphosphoryl]amino]propanoate 2-Ethylbutyl (2S)-2-[[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy]phenoxyphosphoryl]amino]propanoate 2-Ethylbutyl N-[(S)-[2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-D-altrononitril-6-O-yl]phenoxyphosphoryl]-L-alaninate GS 5734 L-Alanine, N-[(S)-hydroxyphenoxyphosphinyl)-, 2-ethylbutyl ester,6-ester with 2-C-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-D-altrononitrile GS-5734 Treatment of viral infections Phase III, clinical trials for the treatment of hospitalized patients with severe …

RESMETIROM

RESMETIROM C17H12Cl2N6O4 435.2 g/mol MGL-3196 CAS 920509-32-6, Resmetirom, VIA-3196, UNII-RE0V0T1ES0 Phase III, Non-alcoholic fatty liver disease (NAFLD) 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-(1,2,4)TRIAZINE-6-CARBONITRILE 1,2,4-TRIAZINE-6-CARBONITRILE, 2-(3,5-DICHLORO-4-((1,6-DIHYDRO-5-(1-METHYLETHYL)-6-OXO-3-PYRIDAZINYL)OXY)PHENYL)-2,3,4,5-TETRAHYDRO-3,5-DIOXO- Madrigal Pharmaceuticals , following the merger between Synta and Madrigal Pharmaceuticals (pre-merger) (following the acquisition of VIA Pharmaceuticals ‘ assets (originally under license from Roche )), is developing resmetirom (MGL-3196, VIA-3196), the lead from oral capsule formulation thyroid hormone receptor …

Coblopasvir

Coblopasvir CAS: 1312608-46-0 Chemical Formula: C41H50N8O8 Molecular Weight: 782.89 UNII-67XWL3R65W methyl {(2S)-1-[(2S)-2-(4-{4-[7-(2-[(2S)-1-{(2S)-2- [(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl)-2H-1,3-benzodioxol-4-yl]phenyl}-1Himidazol-2-yl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate Carbamic acid, N-((1S)-1-(((2S)-2-(5-(4-(7-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-1,3-benzodioxol-4-yl)phenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)-, methyl ester hepatitis C virus infection KW-136 Coblopasvir is an antiviral drug candidate. Coblopasvir dihydrochloride CAS 1966138-53-3 C41 H50 N8 O8 . 2 Cl H Molecular Weight 855.806 PHASE 3 Beijing Kawin Technology Share-Holding Hepatitis C virus (HCV), or hepatitis …